Your browser doesn't support javascript.
loading
Investigating documentation of alcohol and non-medical substance use in oncology treatment: an electronic health record review.
Streck, Joanna M; Walter, Angela W; Temel, Jennifer S; Jawahri, Areej El-; Shin, Hyo Jin; Regan, Susan; Muzikansky, Alona; Ponzani, Colin J; Ostroff, Jamie S; Park, Elyse R.
Afiliação
  • Streck JM; Department of Psychiatry, Massachusetts General Hospital (MGH), Boston, MA, USA. jstreck@mgh.harvard.edu.
  • Walter AW; Tobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, MGH, Boston, MA, USA. jstreck@mgh.harvard.edu.
  • Temel JS; Harvard Medical School, Boston, MA, USA. jstreck@mgh.harvard.edu.
  • Jawahri AE; Health Promotion and Resiliency Intervention Research Program, The Mongan Institute, MGH, Boston, MA, USA. jstreck@mgh.harvard.edu.
  • Shin HJ; Health Promotion and Resiliency Intervention Research Program, The Mongan Institute, MGH, Boston, MA, USA.
  • Regan S; Department of Public Health, University of Massachusetts, Lowell, MA, USA.
  • Muzikansky A; MGH Cancer Center, Boston, MA, USA.
  • Ponzani CJ; MGH Cancer Center, Boston, MA, USA.
  • Ostroff JS; Department of Psychiatry, Massachusetts General Hospital (MGH), Boston, MA, USA.
  • Park ER; Tobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, MGH, Boston, MA, USA.
Support Care Cancer ; 30(5): 4275-4281, 2022 May.
Article em En | MEDLINE | ID: mdl-35088148
ABSTRACT

PURPOSE:

Little is known about non-tobacco substance use (SU) and its treatment in cancer patients. National guidelines address tobacco only, and assessment of SU in cancer patients is not standardized. It is not clear how oncology clinicians assess, document, and follow-up on SU.

METHODS:

We conducted an electronic health record review of patients enrolled in a smoking cessation trial at one large hospital site (N = 176). Chart review of oncology treatment notes assessed whether SU assessment was documented, the content of the documentation/assessment (e.g., frequency of use), and details about documentation (e.g., where/who documented).

RESULTS:

Sixty-nine percent (121/176) of cancer patients had SU documented. Many patients (42%, 74/176) had only one substance documented; 66% (116/176) had alcohol use documented. For a substantial minority of patients (43/176; 24%), the provider did not specify the substance assessed (e.g., "drug use," "illicits"). SU was primarily documented by physicians (84%, 102/121), in routine progress notes (56%, 68/121), in the "social history" section of the note (84%, 102/121). Only 4 patients had a documented SU follow-up plan. When examining the subset of patients who reported problematic alcohol use (N = 27), the content of documentation was inconsistent (e.g., number of drinks/day vs. qualitative descriptors of use).

CONCLUSIONS:

About 1/3 of oncology patients did not have SU assessment documented. SU other than alcohol use was infrequently documented, many clinicians documented SU but did not specify substance type, and few clinicians documented a follow-up plan for problematic SU. Oncology settings should utilize standardized assessment and referral for SU treatment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos Relacionados ao Uso de Substâncias / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos Relacionados ao Uso de Substâncias / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos